| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2030448 | Translational Proteomics | 2014 | 11 Pages |
•Translation of an antibody array discovery.•Multi-antibody sandwich assay.•Biomarker candidate for lymph node metastasis.
There is a need for a better differentiation of aggressive tumors in prostate cancer to design a tailored treatment for each patient, preferably by a minimally invasive analysis of blood samples. In a previous study, we discovered a decrease of plasma levels of carnosine dipeptidase 1 (CNDP1) in association with aggressive prostate cancer. Now this relation has been investigated and characterized further by generating several new antibodies for extended analysis of CNDP1 in plasma. Multi-antibody sandwich assays were developed and applied to 1214 samples from two Swedish cohorts that confirmed decreased levels of CNDP1 in plasma from patients with advanced disease. Therein, data from CNDP1 assays allowed a better differentiation between tumor N stages than clinical tPSA, but did not when classifying T or M stages. Further investigations can now elucidate mechanisms behind decreasing levels of CNDP1 in plasma and primary in regards to lymph node metastasis.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
